Non‐pharmacological biological treatment approaches to difficult‐to‐treat depression

@article{Fitzgerald2012NonpharmacologicalBT,
  title={Non‐pharmacological biological treatment approaches to difficult‐to‐treat depression},
  author={Paul B. Fitzgerald},
  journal={Medical Journal of Australia},
  year={2012},
  volume={199}
}
  • P. Fitzgerald
  • Published 1 October 2012
  • Psychology, Medicine
  • Medical Journal of Australia
There has been substantial recent interest in novel brain stimulation treatments for difficult‐to‐treat depression. Electroconvulsive therapy (ECT) is a well established, effective treatment for severe depression. ECT's problematic side‐effect profile and questions regarding optimal administration methods continue to be investigated. Magnetic seizure therapy, although very early in development, shows promise, with potentially similar efficacy to ECT but fewer side effects. Vagus nerve… 

Pharmacological treatment approaches to difficult-to-treat depression.

There is no strong evidence for the order of implementing evidence-based pharmacological strategies for difficult-to-treat depression, but recommend: i) increase antidepressant dose; ii) switch to different antidepressant; iii) augment with a non-antidepressant agent; and iv) combine antidepressants.

Psychosocial treatment approaches to difficult-to-treat depression.

The evidence base for psychosocial therapies in difficult-to-treat depression is small, with the research heavily weighted toward biological treatments.

Vagus Nerve Stimulation in children: A focus on intellectual disability.

Major depressive disorder

An overview of the current evidence of major depressive disorder, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment, is provided.

Brain Neuromodulation Techniques

With the current rapid growth in neuromodulation technologies and applications, it is timely to review the genesis of the field and the current state of the art in this area.

Evaluation of different vagus nerve stimulation anatomical targets in the ear by vagus evoked potential responses

This work aims to define the best auricular target for taVNS through vagus somatosensory evoked potential (VSEP) elicited stimulating different auricular areas with different electrode sizes.

Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53

Necrosis, unregulated cell death, is characterized by plasma membrane rupture as well as nuclear and cellular swelling. However, it has recently been reported that necrosis is a regulated form of

Neural activity changes in first-episode, drug-naïve patients with major depressive disorder after transcutaneous auricular vagus nerve stimulation treatment: A resting-state fMRI study

The regional homogeneity (ReHo) was used to investigate the brain activity in first-episode, drug-naïve MDD patients after taVNS treatment to find the sensorimotor, limbic and visual-related brain regions may play an important role in understanding the underlying neural mechanisms and be the target brain regions in the further therapy.

Comparative Effectiveness of Transcutaneous Auricular Vagus Nerve Stimulation vs Citalopram for Major Depressive Disorder: A Randomized Trial.

  • Shaoyuan LiP. Rong J. Kong
  • Psychology, Medicine
    Neuromodulation : journal of the International Neuromodulation Society
  • 2021

References

SHOWING 1-10 OF 33 REFERENCES

Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years.

Deep brain stimulation remains a safe and effective treatment for treatment-resistant depression and functional impairment in the areas of physical health and social functioning progressively improved up to the last follow-up visit.

Vagus nerve stimulation in depression

Longer term data regarding symptomatic and functional outcomes of depressed patients receiving VNS continue to look promising, similar to findings in epilepsy and in contrast to the usual results of long-term medication trials.

Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial

Findings confirm earlier reports of the antidepressant efficacy and safety of tDCS and Vigilance for mood switching is advised when administering tDCS to individuals with bipolar disorder.

A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression.

There was a low incidence of accidental seizures and induced hypomania, both of which were associated with identified risk factors for which subjects should be screened, and supports its further development as a clinical treatment.

Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.

Daily left prefrontal repetitive transcranial magnetic stimulation as monotherapy produced statistically significant and clinically meaningful antidepressant therapeutic effects greater than sham.